ArticleTranslational cancer research2025
The influence of CXCL9 on M2 macrophages in lung cancer development.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MicroRNA regulation of macrophage polarization in lung cancer: Regulatory networks and therapeutic potential (Review).International journal of oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer has the highest incidence among malignant tumors, and its high degree of metastasis and invasion, tendency to metastasis, and mortality rate are the key factors leading to treatment failure and poor prognosis. Tumor-associated macrophages (TAMs), which often exhibit an M2-polarized phenotype, are known to promote tumor progression. Notably, the chemokine CXCL9 has emerged as a critical regulator that can inhibit M2 macrophage polarization, thereby potentially suppressing tumor growth. This study combined clinical sample testing and prognostic analysis with cell behaviorology and molecular biology to systematically investigate the role and regulatory mechanism of CXCL9 in the tumor microenvironment of lung cancer. Methods: THP-1 cells were induced to differentiate into M1 and M2 macrophages. The effects of M2 macrophages on the proliferation, migration, and invasion of A549 lung adenocarcinoma cells were detected via Cell Counting Kit-8 cell viability, scratch-wound, and Transwell invasion assays. The effects of CXCL9 on M2 macrophage function and the expression of related proteins were detected via enzyme-linked immunosorbent assay, reverse transcription polymerase chain reaction, and Western blotting. Results: CXCL9 significantly inhibited the promoting effects of M2 macrophages on the proliferation, migration, metastasis and invasion of A549 cells. Specifically, CXCL9 inhibited M2 macrophage polarization by reducing the expression of surface markers CD16, CD32, and CD206. CXCL9 also inhibited the expression of VEGF-C, MMP9, and MMP2, thereby inhibiting tumor cell invasion and metastasis. Moreover, CXCL9 inhibited the activation of the ERK and AKT signaling pathways, further inhibiting tumor cell proliferation and invasion. Conclusions: CXCL9 inhibits the proliferation, migration, metastasis and invasion of lung cancer cells by inhibiting M2 macrophage polarization and function, indicating that CXCL9 may serve as a potential therapeutic target for lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.